胸腺状细胞癌患者的生存名录,基于SEER数据库和外部验证队列
Yelan Guan1,2, Feiqi Xu3, Shuai Zheng4
1Department of Clinical Trial, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, Zhejiang, China.
Discover oncology
|June 20, 2023
概括
一种新型的诺米图准确地预测了胸腺状细胞癌 (TSCC) 患者的存活率. 该工具有助于临床医生评估TSCC的预后并做出明智的治疗决策.
科学领域:
- 在瘤学瘤学.
- 医学统计 医学统计
背景情况:
- 胸膜状细胞癌 (TSCC) 是一种罕见的恶性瘤,预后可变.
- 准确预测患者的生存率对于有效的治疗规划和管理至关重要.
研究的目的:
- 开发和验证TSCC诊断的患者的3年和5年整体生存期的预测性名谱.
- 确定影响TSCC生存结果的关键预后因素.
主要方法:
- 一项回顾性队列研究,使用来自监测,流行病学和最终结果 (SEER) 数据库 (n=355) 的数据作为培训套件.
- 外部验证使用江癌症医院 (n=106) 的数据进行.
- 使用Cox比例危险回归识别了预后因素,并构建了一个名录,并对准确性 (C指数) 和校准进行了验证.
主要成果:
- 年龄,阶段,手术和放射治疗被确定为TSCC患者整体存活时间的独立预后因素.
- 开发的名图表显示出良好的区别,C指数值为0.696 (培训) 和0.717 (验证).
- 患者被分为低风险和高风险组,在两个队列中显示出显著的生存差异 (p<0.0001).
结论:
- 成功开发了一种可靠的诺姆图,用于预测胸膜状细胞癌的3年和5年生存率.
- 这种预测工具为临床医生提供了一种方便可靠的方法来评估患者的病情,并指导TSCC的治疗策略.
相关概念视频
Cancer Survival Analysis
402
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
402
Kaplan-Meier Approach
195
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
195


